6,500 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Bought by Virtus Investment Advisers Inc.

Virtus Investment Advisers Inc. bought a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the third quarter, Holdings Channel.com reports. The firm bought 6,500 shares of the company’s stock, valued at approximately $98,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in Pacira BioSciences by 229.6% in the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after buying an additional 932 shares in the last quarter. Innealta Capital LLC bought a new stake in shares of Pacira BioSciences during the second quarter valued at about $50,000. nVerses Capital LLC lifted its holdings in Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after purchasing an additional 1,600 shares during the period. CWM LLC grew its position in Pacira BioSciences by 713.6% in the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after buying an additional 5,716 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in Pacira BioSciences during the 2nd quarter valued at about $113,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Stock Performance

Pacira BioSciences stock opened at $19.27 on Friday. The company has a 50 day moving average price of $16.86 and a 200 day moving average price of $19.48. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $35.95.

Analyst Ratings Changes

Several research analysts have recently issued reports on PCRX shares. HC Wainwright reiterated a “buy” rating and issued a $39.00 price objective on shares of Pacira BioSciences in a report on Wednesday. Truist Financial lowered Pacira BioSciences from a “buy” rating to a “sell” rating and cut their price objective for the company from $30.00 to $8.00 in a report on Tuesday, August 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Pacira BioSciences in a report on Friday, November 8th. Barclays cut their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a report on Tuesday, November 12th. Finally, Raymond James cut shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research note on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.